Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM (TESSTAL)
|ClinicalTrials.gov Identifier: NCT00490789|
Recruitment Status : Unknown
Verified April 2008 by Cardiff University.
Recruitment status was: Active, not recruiting
First Posted : June 25, 2007
Last Update Posted : April 30, 2008
University of Nottingham
St Georges Hospital Medical School
Royal Sussex County Hospital
The Tuberous Sclerosis Association
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 2009|
|Estimated Study Completion Date :||September 2009|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
|1||May 18, 2012||June 19, 2012|
|2||January 30, 2017||March 22, 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011 Jun 15;17(12):4071-81. doi: 10.1158/1078-0432.CCR-11-0445. Epub 2011 Apr 27.